China NMPA Drug Inspection - Tiansheng Pharmaceutical Group Shanxi Co., Ltd. - Cold and Fever Relief Granules

The Guangxi Zhuang Autonomous Region Food and Drug Administration published its Drug Quality Announcement (2018, Issue 4) on April 28, 2018, detailing findings from a comprehensive drug quality sampling inspection. These inspections, conducted under the Guangxi drug sampling plan, aimed to reinforce drug quality oversight and safeguard public health across various drug production, distribution, and medical institutions.

The announcement identified three batches of drugs failing to meet quality standards. Shaanxi Junbisha Pharmaceutical Co., Ltd.'s "Skin Disease Blood Toxicity Tablets" (batch 20160616) were found non-compliant regarding their appearance and weight uniformity. Guizhou Tiandi Pharmaceutical Co., Ltd.'s "Adenosine Triphosphate Disodium Injection" (batch 16122601B) contained visible foreign matter, violating the specifications of the Chinese Pharmacopoeia 2010 Edition, Part II. Furthermore, Tiansheng Pharmaceutical Group Shanxi Granules Co., Ltd.'s "Cold and Fever Relief Granules (Sugar-free)" (batch 150501) showed non-compliant moisture content, contravening the Chinese Pharmacopoeia 2010 Edition, Third Supplement.

In response to these findings, the Guangxi Food and Drug Administration initiated immediate control measures, including the sealing, seizing, and suspension of sales for all substandard drug batches. Additionally, the administration has launched investigations and mandated legal actions against the manufacturing companies responsible for these quality deficiencies, ensuring adherence to established regulatory standards.